The Maharashtra Food and Drug Administration (FDA) has banned the sale and distribution of select medicines manufactured by Cadila Pharmaceuticals Ltd and seized stock worth ₹2,45,37,490, citing concerns that near-identical branding on products with different active ingredients could trigger dangerous medication errors. The action, taken following inspections on 9 and 10 July, also directs the company to initiate a product recall.

The Drugs at the Centre of the Action

The crackdown targets four products: Aciloc 150, Aciloc 150 Plus, Aciloc 300, and Aciloc 300 Plus. While Aciloc 150 and Aciloc 300 were originally approved with Ranitidine as the active pharmaceutical ingredient (API), the company subsequently introduced the 'Plus' variants containing Famotidine — a different API — while retaining nearly identical packaging and artwork, with only the addition of a '+' symbol to distinguish them.

Both Ranitidine and Famotidine are used to reduce stomach acid, but they are distinct compounds with different dosing protocols and contraindication profiles. The FDA warned that their simultaneous availability under virtually the same brand name creates a serious risk of dispensing or consuming the wrong drug.

What the Regulator Found and Where

Maharashtra FDA inspectors visited the carrying and forwarding agent warehouses of Cadila Pharmaceuticals in Pune, Nagpur, and Bhiwandi in Thane district on 9 and 10 July. During these inspections, the available stock of the four medicines was prohibited from sale and distribution. The total value of seized stock stands at ₹2,45,37,490.

The regulator also directed the company to recall the select products from the broader market, signalling that the concern extends beyond warehouse stock to medicine already in circulation.

What the FDA Commissioner Said

FDA Commissioner Tukaram Mundhe stated that any confusion arising from a medicine's brand name that could result in doctors, pharmacists, or patients receiving the wrong drug constitutes a serious public health concern. Existing guidelines, he noted, prohibit marketing medicines with a changed composition under substantially the same brand name.

The regulator described the preventive action as necessary to safeguard public health and confirmed that further investigation is underway. Legal proceedings are expected under the Drugs and Cosmetics Act, 1940, and the rules framed thereunder, based on investigation findings.

Broader Public Health Implications

This action highlights a recurring regulatory challenge in India's pharmaceutical sector: brand name proliferation that outpaces label differentiation. When a manufacturer changes an active ingredient while retaining near-identical branding, the burden of error falls disproportionately on pharmacists and patients — particularly in high-volume, over-the-counter settings where packaging is the primary reference point.

Notably, Ranitidine itself has had a troubled regulatory history globally, having been withdrawn in several markets over concerns about NDMA contamination. The transition to Famotidine-based variants under the same brand umbrella, without clear visual differentiation, adds another layer of concern that regulators and prescribers will be watching closely.

With the investigation ongoing and legal action under the Drugs and Cosmetics Act anticipated, the outcome could set a precedent for how Indian drug regulators treat brand-name similarity as a patient safety risk going forward.